Who are GentiBio's investors?

GentiBio's investors include Novartis Venture Fund, OrbiMed, JDRF T1D Fund, RA Capital.

How much funding has GentiBio raised?

GentiBio has disclosed $20M raised across 1 of its 2 known rounds.

GentiBio

Founded 2020 · 43 employees on LinkedIn · 4 known investors

Find your way into GentiBio

517 people in our graph share verified history with the GentiBio team — schools, employers, funds. One of them is your warm intro.

Dougunlockedknows Chandra Patel · together at University of Texas (overlapped)

×2knows the team · via Bayer HealthCare

×5knows the team · via University of Kentucky

×3knows the team · via NIH

knows the team · via Baylor College of Medicine

GentiBio develops engineered regulatory T-cell (EngTreg) therapies designed to reset the immune system and treat autoimmune and acute inflammatory diseases. The company builds autologous and allogeneic Treg platforms as an alternative to systemic immune-suppressive therapies.

Biotech Healthtech Medical Devices

Founders & leadership

GentiBio was founded in 2020 by Jane Buckner, Chandra Patel, David Rawlings, and Andy Scharenberg.

Jane BucknerScientific Co-founder (President, Benaroya Research Institute)

Chandra Patel inCo-founder & SVP, Research and Development OperationsChandra Patel has led preclinical research and development programs across cell therapy, gene therapy, and small molecule therapeutics, with expertise in hematology and autoimmune disease. Prior to GentiBio, Patel managed academic collaborations and regulatory engagement with the FDA and European medicines authorities.

David RawlingsScientific Co-founder and Senior Scientific Advisor

Andy ScharenbergScientific Co-founder, SAB Chair

Andy WalkerinPresident and CEO

Tom WickhamChief Scientific Officer

Mark Bach inChief Medical OfficerMark Bach is Chief Medical Officer at GentiBio with over 30 years of pharmaceutical experience spanning clinical sciences, clinical research operations across Asia-Pacific and global markets, and prior biotech leadership roles including involvement in an IPO process.

Investors · 4

Novartis Venture Fund✓ verifiedBasel · $5M – $25M

OrbiMed✓ verifiedNew York · $1M – $75M

JDRF T1D FundBoston

RA CapitalBoston

Funding

SEC filings, press & company announcements

$20M disclosed across 1 of 2 rounds · 2020–2021

$20MSeed FundingAug 2020 · 2 sources
Novartis Venture Fund, OrbiMed, RA Capital Management, L.P.
Source ↗

Source: company announcements and press reports — follow each round's link for the claim.

Competitors · 3

by search overlap

Bridgebio58 shared keywordsBridgeBio develops treatments for genetic conditions and cancers using a decentralized hub-and-spoke model, where autonomous teams focus on specific diseases or drug candidates while a central hub provides clinical, regulatory, and commercial support. The company partners with academic institutions to advance early-stage research toward late-stage clinical trials.

Bioworld49 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.

AskBio37 shared keywordsAskBio is a gene therapy company developing adeno-associated virus (AAV)-based genetic medicines for rare and other diseases, with clinical programs such as AB-1009 for late-onset Pompe disease. It operates as a wholly owned, independent subsidiary of Bayer AG.

Companies competing with GentiBio for the same Google search keywords, organic and paid, via search-intersection analysis.

In the news

Sell or Invest in GentiBio Stock Pre-IPOnasdaqprivatemarket.com · Jun 2025

GentiBio raises $157M as cell therapy for immune diseases draw investor interest | BioPharma Divebiopharmadive.com · Aug 2021

GentiBio Launches with $20M Seed Funding from OrbiMed, Novartis Venture Fund and RA Capital Management, L.P. to Develop Engineered Regulatory T cells to Deliver Immune Tolerizing Therapies for Autoimmune and Inflammatory Diseases - GentiBiogentibio.com · Aug 2020

GentiBio Raises $20M in Seed Funding - FinSMEsfinsmes.com · Aug 2020

Frequently asked questions

What does GentiBio do?: GentiBio develops engineered regulatory T-cell (EngTreg) therapies designed to reset the immune system and treat autoimmune and acute inflammatory diseases. The company builds autologous and allogeneic Treg platforms as an alternative to systemic immune-suppressive therapies.
Who founded GentiBio?: GentiBio was founded by Jane Buckner, Chandra Patel, David Rawlings, Andy Scharenberg in 2020.
Who are GentiBio's investors?: GentiBio's investors include Novartis Venture Fund, OrbiMed, JDRF T1D Fund, RA Capital.
How much funding has GentiBio raised?: GentiBio has disclosed $20M raised across 1 of its 2 known rounds.